Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc. (NASDAQ:LYEL), filed a Form 4 on August 11, 2026, reporting an automatic sale of common stock on August 10, 2026, to cover tax withholding obligations arising from the settlement of vested restricted stock units.

Key Highlights

  • Reporting person: Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc.
  • Transaction date: August 10, 2026
  • Shares disposed: 131 shares of common stock sold, coded "S" (disposed of, direct ownership)
  • Weighted average sale price: $14.34 per share, with individual sale prices ranging from $14.22 to $14.34 per share
  • Purpose of sale: Shares were automatically sold to cover tax withholding obligations from settlement of vested restricted stock units
  • Beneficial ownership following transaction: 17,677 shares of common stock held directly

Automatic Tax-Withholding Sale by Lyell Immunopharma's Chief Scientific Officer

According to the Form 4 filed with the SEC on August 11, 2026, Gary K. Lee, serving as Chief Scientific Officer of Lyell Immunopharma, Inc., disposed of 131 shares of common stock on August 10, 2026. The filing notes that the shares were "automatically sold to cover tax withholding obligation from settlement of vested restricted stock units," rather than a discretionary open-market sale initiated by the reporting person.

The filing reports a weighted average sale price of $14.34 per share. Per the filing's explanation of responses, "the sale price ranged from $14.22 to $14.34 per share," and the filing states that upon request from the SEC staff, the issuer, or a security holder, the reporting person will provide full information regarding the number of shares sold at each separate price within that range. Following the reported transaction, Lee directly held 17,677 shares of Lyell Immunopharma common stock.

The Form 4 was signed by Mark Meltz as Attorney-in-Fact on behalf of the reporting person and was dated August 11, 2026. No derivative securities transactions were reported in Table II of the filing. Lee's address of record is listed as c/o Lyell Immunopharma, Inc., 201 Haskins Way, South San Francisco, California 94080.

What Was Disclosed

The filing disclosed an automatic sale of 131 shares of Lyell Immunopharma common stock by Chief Scientific Officer Gary K. Lee on August 10, 2026, at a weighted average price of $14.34, solely to satisfy tax withholding obligations on vested restricted stock units, leaving Lee with 17,677 directly held shares.